Skip to content
value.today
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

Total raised
$91 M
3 rounds on record
Latest round
$80 M
Oct 2018
First round on record
Jun 2015
Today
Went public
See the company page

Milestone Pharmaceuticals Inc. is listed today as Milestone Pharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Milestone Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$80 MNo. 3$50 to $250 million

Milestone Pharmaceuticals Inc.: Raise no. 3, Oct 2018

Investors in this round

16 investors had bought by the notice of Oct 26, 2018: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Milestone Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Quebec, Canada

People named in the notice

  • Douglas G. Wight · Executive Officer
  • Francis G. Plat · Executive Officer
  • Guy G. Rousseau · Executive Officer
  • Harish G. Pimplaskar · Executive Officer
  • Jeff G. Nelson · Executive Officer
  • Joseph G. Oliveto · Executive Officer, Director
  • Lorenz G. Muller · Executive Officer
  • Philippe G. Douville · Executive Officer
  • Debra G. Liebert · Director
  • Marco G. Boorsma · Director
  • Nilesh G. Kumar · Director
  • Paul G. Truex · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph G. Oliveto, President and CEO. Source: SEC Form D, newest notice filed Oct 26, 2018. Read the notice at the SEC.

equitySEC
Jul 2017$7 MNo. 2$2 to $10 million

Milestone Pharmaceuticals Inc.: Raise no. 2, Jul 2017

Investors in this round

5 investors had bought by the notice of Jul 25, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Milestone Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Quebec, Canada

People named in the notice

  • Douglas G. Wight · Executive Officer
  • Francis G. Plat · Executive Officer
  • Guy G. Rousseau · Executive Officer
  • Joseph G. Oliveto · Executive Officer, Director
  • Martin G. Maguire · Executive Officer
  • Philippe G. Douville · Executive Officer
  • Debra G. Liebert · Director
  • Dion G. Madsen · Director
  • Marco G. Boorsma · Director
  • Nilesh G. Kumar · Director
  • Paul G. Truex · Director
  • Scott G. Weiner · Director
  • Yves G. Rosconi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph G. Oliveto, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 25, 2017. Read the notice at the SEC.

equitySEC
Jun 2015$4 MNo. 1$2 to $10 million

Milestone Pharmaceuticals Inc.: Raise no. 1, Jun 2015

Investors in this round

3 investors had bought by the notice of Jun 15, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Milestone Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $9 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Benjamin Cowen · Executive Officer
  • Douglas Wight · Executive Officer
  • Francis Plat · Executive Officer
  • Martin Maguire · Executive Officer
  • Nathalie Beauregard · Executive Officer
  • Paul Truex · Executive Officer, Director
  • Philippe Douville · Executive Officer, Director
  • Debra Liebert · Director
  • Ela Borenstein · Director
  • Scott Weiner · Director
  • Yves Rosconi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philippe Douville, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 15, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Milestone Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2018).

    SEC Form D · Oct 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2018

That is all the official record says: Milestone Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Milestone Pharmaceuticals Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Milestone Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
BDC Capital Inc.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Fonds De Solidarite Des Travailleurs Du QuebecPersonnot statednot statedHeld Series A-1, A-2, B, C and D-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Philippe DouvillePersonnot statednot statedHeld preferred stock (Form 3, 2019)SEC Form 3
RTW Investments, LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding Milestone Pharmaceuticals Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Milestone Pharmaceuticals Inc.
NameRoleNamed in
Douglas G. WightExecutive officerOct 2018
Francis G. PlatExecutive officerOct 2018
Guy G. RousseauExecutive officerOct 2018
Harish G. PimplaskarExecutive officerOct 2018
Jeff G. NelsonExecutive officerOct 2018
Joseph G. OlivetoExecutive officerOct 2018
Lorenz G. MullerExecutive officerOct 2018
Philippe G. DouvilleExecutive officerOct 2018
Martin G. MaguireExecutive officerJul 2017
Benjamin CowenExecutive officerJun 2015
Douglas WightExecutive officerJun 2015
Francis PlatExecutive officerJun 2015
Martin MaguireExecutive officerJun 2015
Nathalie BeauregardExecutive officerJun 2015
Paul TruexExecutive officerJun 2015
Philippe DouvilleExecutive officerJun 2015
Debra G. LiebertDirectorOct 2018
Joseph G. OlivetoDirectorOct 2018
Marco G. BoorsmaDirectorOct 2018
Nilesh G. KumarDirectorOct 2018
Paul G. TruexDirectorOct 2018
Dion G. MadsenDirectorJul 2017
Scott G. WeinerDirectorJul 2017
Yves G. RosconiDirectorJul 2017
Debra LiebertDirectorJun 2015
Ela BorensteinDirectorJun 2015
Paul TruexDirectorJun 2015
Philippe DouvilleDirectorJun 2015
Scott WeinerDirectorJun 2015
Yves RosconiDirectorJun 2015

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.